The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables

Author

  • HK Johannsdottir
  • G Johannesdottir
  • BA Agnarsson
  • H Eerola
  • A Arason
  • OT Johannsson
  • P Heikkila
  • V Egilsson
  • Håkan Olsson
  • Åke Borg
  • H Nevanlinna
  • RB Barkardottir

Summary, in English

Background: Chromosomal aberrations in breast tumors from BRCA1 and BRCA2 germ-line mutation carriers are considerably more frequent than what is seen in sporadic breast tumors. According to Comparative Genomic Hybridisation analysis (CGH), deletions on chromosome 4 are one of the most frequent events in BRCA1-associated tumors, suggesting inactivation of specific tumor suppressor genes. Materials and Methods: In the present study, 16 microsatellite markers covering chromosome 4 were used to map loss of heterozygosity (LOH) in tumors from BRCA1 (n =41) as well as in tumors from BRCA2 (n = 66) mutation carriers and in tumors from unselected cases of breast cancer (n = 68). Results: The frequency of LOH in these groups ranged from 16-73% in BRCA1-associated tumors, 13-42% in BRCA2-associated tumors and 8-33% in unselected tumors. LOH was significantly more frequent in BRCA1-associated tumors as compared to BRCA2-associated tumors and unselected tumors, and particularly high (over 70%) at 4q35.2. Pathological variables that were found significantly associated (pless than or equal to0.05) with LOH at specific markers were: high percentage of cells in S-phase, negative estrogen receptor status, young age at diagnosis and large tumors. Deletion mapping indicates the existence of seven non-overlapping regions at chromosome 4, which were identified in all three groups of tumors. Three of these seven regions, 4p16.3-p16.1, 4q27-q32.1 and 4q35.1-4qter, have not been reported in breast cancer previously. Conclusion: The results manifest the frequent alterations of chromosome 4 in BRCA1-associated breast tumors and indicate the location of several genes of potential importance in breast cancer development.

Department/s

  • Breastcancer-genetics

Publishing year

2004

Language

English

Pages

2681-2687

Publication/Series

Anticancer research

Volume

24

Issue

5A

Document type

Journal article

Publisher

International Institute of Cancer Research

Topic

  • Cancer and Oncology

Keywords

  • BRCA2
  • breast cancer
  • BRCA1
  • loss of heterozygosity

Status

Published

ISBN/ISSN/Other

  • ISSN: 1791-7530